On November 9, 2021, ICER released its draft evidence report, “Tirzepatide for Type 2 Diabetes.” This document provides a framework for considering what aspects of tirzepatide – a potential new treatment for diabetes – are important to patients and their families, and how to consider presenting those perspectives. This guide specifically provides insights about how to read and respond to ICER’s draft evidence report, as well as how to request a slot to make comments during ICER’s public meeting.
